Berlin, Germany

Erhard Klauschenz

This inventor holds 1 USPTO granted patent. Top assignee: Arzneimittelwerk Dresden Gmbh. Active years: 1992.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 1992

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Erhard Klauschenz: Innovator in Pharmaceutical Compounds

Introduction

Erhard Klauschenz is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of pharmaceuticals, particularly with his innovative compounds that exhibit heart-stimulating properties. His work has implications for cardiotonic and vasodilatory applications, showcasing the potential for advancements in medical treatments.

Latest Patents

Klauschenz holds a patent for a compound known as 3-cyano-5,4'-bipyridine-1'-oxide. This compound, along with its pharmaceutically acceptable acid addition salts, demonstrates heart-stimulating cardiotonic and vasodilatory properties. The patent outlines methods for preparing these compounds, including converting an R-substituted-3-cyano-bipyridine to its corresponding N-oxide or substituting an R-residue in the compound's structure.

Career Highlights

Throughout his career, Klauschenz has been associated with Arzneimittelwerk Dresden GmbH, where he has focused on developing innovative pharmaceutical solutions. His expertise in chemical compounds has led to advancements that could benefit cardiovascular health.

Collaborations

Klauschenz has worked alongside notable colleagues such as Gottfried Faust and Volker Hagen. Their collaborative efforts have contributed to the development of new pharmaceutical compounds and research initiatives.

Conclusion

Erhard Klauschenz is a distinguished inventor whose work in pharmaceutical compounds has the potential to impact medical treatments significantly. His innovative approach and collaboration with other experts in the field highlight the importance of teamwork in advancing healthcare solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…